SCYNEXIS INC
SCYXNASDAQTrading Snapshot
- Day Range
- $4.77 – $4.89
- 52-Week Range
- $3.53 – $10.48
- Volume
- $3.32B
- Avg Volume
- $2.64B
- Shares Outstanding
- 9.9M
- Next Earnings
- Oct 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $21M
- Last Q Revenue
- $235,000
- P/E Ratio
- —
- P/S Ratio
- 2.5x
- EPS (TTM)
- $-2.92
- Dividend Yield
- —
Why Investors Own SCYX
- ✓High-growth profile — revenue up +52.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SCYNEXIS INC
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Initiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for the planned Phase 2 study The Phase 2 proof-of-concept study of SCY-770 in patients with ADPKD remains on track for initiation in Q4 2026, with an early efficacy read-out expected in the second half of 2027Completed dosing in the Phase 1 study of the IV formulation of second-generation antifungal SCY
UPDATE: SCYNEXIS Q2 Adj. EPS $(0.57) Misses $(0.51) Estimate, Sales $235.000K Beat $80.330K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.51) by 11.76 percent. This is a 49.11 percent increase over losses of $(1.12) per share from the
SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $(0.64) by 198.44 percent. This is a 156.25 percent increase over losses of $(1.12) per share from the
Top movers in Friday's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is at
Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pediatric Use Information And Revised Patient Safety Guidance
https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2636#